DURHAM, N.C., and SAN DIEGO (PRWEB) August 05, 2019
Sepsis Alliance, the nation’s leading sepsis organization, and bioMérieux, a world leader in the field of in vitro diagnostics, today announced their renewed collaboration to increase healthcare provider education on sepsis with the webinar series, Sepsis: Across the Continuum of Care.
Sepsis is the body’s life-threatening response to an infection that affects 1.7 million people and takes 270,000 lives a year in the United States. The condition takes more lives annually than prostate cancer, breast cancer and opioid overdoses combined.
Sepsis: Across the Continuum of Care provides education on sepsis and related topics for healthcare providers across the entire continuum of care, from critical care to home care staff. Future webinars will include: Artificial Intelligence in Sepsis Care, Sepsis and Respiratory Disease, Sepsis and Antimicrobial Stewardship, among others. bioMérieux has supported the series since it began in late 2017.
“bioMérieux’s commitment to Sepsis: Across the Continuum of Care has enabled us to reach tens of thousands of healthcare providers, and that reach is multiplied when you consider all the patients they care for,” said Thomas Heymann, President and Executive Director, Sepsis Alliance. “We are very proud to work with an organization that shares our dedication to reducing sepsis mortality rates and improving outcomes for patients through education and awareness.”
Together, bioMerieux and Sepsis Alliance have collaborated for five years in an effort to inform the public about the dangers and risk factors of sepsis and to promote clinical best-practices for early detection, diagnosis and treatment of this devastating condition.
bioMérieux is also a 2019 Public Education Sponsor of the 8th Annual Sepsis Heroes gala, which will take place on September 12, 2019, in New York City, NY. This annual event, timed to coincide with Sepsis Awareness Month, honors Sepsis Heroes who have made a significant contribution to sepsis awareness and education among both the general public and healthcare professionals.
To learn more about Sepsis: Across the Continuum of Care, and register for upcoming webinars, please visit http://www.sepsiswebinar.org. For information about the 8th Annual Sepsis Heroes gala, please visit http://www.sepsisheroes.org.
Unless clearly marked as sponsor-presented content, it is Sepsis Alliance’s policy that funders and sponsors may not contribute to or influence the health information, educational content, or any other content on the Sepsis Alliance website, or any Sepsis Alliance communication, including webinars. For more information on Sepsis Alliance’s funding and sponsorship policy, please visit http://www.sepsis.org/about/funding-and-sponsorship-policy/.
About Sepsis Alliance
Sepsis Alliance is the leading sepsis organization in the U.S., working in all 50 states to save lives and reduce suffering by raising awareness of sepsis as a medical emergency. In 2011, Sepsis Alliance designated September as Sepsis Awareness Month to bring healthcare professionals and community members together in the fight against sepsis. In 2018, Sepsis Alliance created the award-winning national campaign, Sepsis: It's About T.I.M.E.™, to educate the public about the signs and symptoms of sepsis and to highlight the urgent need to seek treatment when symptoms are recognized. Sepsis Alliance gives a voice to the millions of people who have been touched by sepsis – to the survivors, and the friends and family members of those who have survived or who have died. Since 2007, sepsis awareness in the U.S. has risen from 19% to 65%. Sepsis Alliance is a GuideStar Platinum Rated charity. For more information, please visit http://www.sepsis.org. Connect with us on Facebook and Twitter at @SepsisAlliance.
A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 43 countries and serves more than 160 countries with the support of a large network of distributors. In 2018, revenues reached €2.4 billion, with over 90% of international sales.
bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases and some critical illnesses. Its diagnostic solutions are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: http://www.biomerieux.com
Investor website: http://www.biomerieux-finance.com
Sepsis Informational Website: http://www.sepsisknowfromday1.com
For information on the value of diagnostics in sepsis intervention, infectious diseases and antibiotic stewardship: https://www.biomerieuxconnection.com/